Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

Jeffrey A Berinstein, Taylor Karl, Anish Patel, Michael Dolinger, Terrence A Barrett, Waseem Ahmed, Ben Click, Calen A Steiner, David Dulaney, Jake Levine, Syed Adeel Hassan, Courtney Perry, Deborah Flomenhoft, Ryan C Ungaro, Elliot M Berinstein, Jessica Sheehan, Shirley Cohen-Mekelburg, Randolph E Regal, Ryan W Stidham, Shrinivas BishuJean-Frederic Colombel, Peter D R Higgins

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy.

METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions.

RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted.

DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.

Original languageEnglish
JournalAmerican Journal of Gastroenterology
StateE-pub ahead of print - 27 Mar 2024


Dive into the research topics of 'Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience'. Together they form a unique fingerprint.

Cite this